In Phase II clinical trials, researchers use the safe dose identified in Phase I to evaluate how effective the treatment is for multiple myeloma, while continuing to monitor safety. 

Endpoints shift toward measuring the treatment’s impact on myeloma, with a focus on how well it controls or reduces myeloma. Key endpoints include overall response rate (ORR), progression-free survival (PFS), and duration of response (DoR), which provide insight into how well the treatment manages the myeloma. Achieving positive results here supports advancement to Phase III trials for broader evaluation.